CHS Pharma Inc.
Dedicated to the commercialization of an innovative treatment for a precancerous skin condition commonly known as Actinic Keratosis.
Rapidly emerging Pre-Clinical stage biotech company. The company has acquired its IP portfolio that was previously licensed from Florida Atlantic University (FAU) and Hospital for Special Surgery (HSS). We currently have 4 US patents issued, 1 EU and 1 US patent allowed, and 8 other applications are pending. Our first drug, CHS-101, selectively destroys cancer cells while protecting healthy cells.